Summary
Celgene announces positive preliminary data from its study treating patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) using JCAR017.
A key risk is whether or not hospitals and insurers will pay the hefty price tag of CAR-T therapies, which may impact sales.
Of the 81% of patients that got an ORR who were treated with JCAR017, 43% achieved a complete response.
It is estimated that the global CAR-T cell therapy market could be worth $8 billion by 2028.
Competition is strong in the lymphoma space using CAR-T. Such companies are, for instance, Novartis with Kymriah and Gilead Sciences with Yescarta.
Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our model portfolio. Start your free trial today ยป
Recently, Celgene (CELG) announced preliminary data from its study treating patients with relapsed/refractory (r/r) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The data shown was from the dose escalation part of an ongoing, open-label multicenter phase 1/2 study using JCAR017 to treat these patients. I think that the preliminary data is strong, especially when you consider that a large chunk of this population were given prior treatment with ibrutinib and had cytogenetic features of high-risk disease. This data is preliminary, but it is quite strong.

